Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Medicinova Inc
(NQ:
MNOV
)
1.360
+0.030 (+2.26%)
Streaming Delayed Price
Updated: 2:21 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,122
Open
1.320
Bid (Size)
1.340 (31)
Ask (Size)
1.370 (1)
Prev. Close
1.330
Today's Range
1.320 - 1.390
52wk Range
1.260 - 2.660
Shares Outstanding
49,046,246
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Friday's After-Market Session
April 05, 2024
Via
Benzinga
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
April 02, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Performance
YTD
-17.58%
-17.58%
1 Month
-1.45%
-1.45%
3 Month
-8.11%
-8.11%
6 Month
-29.17%
-29.17%
1 Year
-37.33%
-37.33%
More News
Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 27, 2024
Via
Benzinga
Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
March 27, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 27, 2024
Via
InvestorPlace
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
March 26, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
March 20, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
March 12, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 13, 2024
Via
Benzinga
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
January 17, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
December 21, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
December 06, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 20, 2023
Via
Benzinga
Why Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?
November 20, 2023
Via
Benzinga
Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket
November 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 20, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
November 20, 2023
Via
InvestorPlace
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
November 19, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
October 27, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
October 10, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives Gene Therapy Milestone Payment
October 04, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
September 27, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
August 17, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.